{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:29:04Z","timestamp":1794086944291,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-023-00840-4","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T11:02:54Z","timestamp":1703070174000},"page":"284-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dapagliflozin administration for 1\u00a0year promoted kidney enlargement in patient with ADPKD"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-3634","authenticated-orcid":false,"given":"Shinya","family":"Nakatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Uedono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"9569","key":"840_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(07)60601-1.","journal-title":"Lancet"},{"issue":"9981","key":"840_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G, Diseases E-EWGfIK. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993\u20132002. https:\/\/doi.org\/10.1016\/S0140-6736(15)60907-2.","journal-title":"Lancet"},{"issue":"9","key":"840_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00467-021-05406-z","volume":"37","author":"A Dachy","year":"2022","unstructured":"Dachy A, Decuypere JP, Vennekens R, Jouret F, Mekahli D. Is autosomal dominant polycystic kidney disease an early sweet disease? Pediatr Nephrol. 2022;37(9):1945\u201355. https:\/\/doi.org\/10.1007\/s00467-021-05406-z.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"840_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2215\/CJN.13291019","volume":"15","author":"KL Nowak","year":"2020","unstructured":"Nowak KL, Hopp K. Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential. Clin J Am Soc Nephrol. 2020;15(4):577\u201384. https:\/\/doi.org\/10.2215\/CJN.13291019.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"840_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1681\/ASN.2015020132","volume":"27","author":"G Warner","year":"2016","unstructured":"Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, et al. Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol. 2016;27(5):1437\u201347. https:\/\/doi.org\/10.1681\/ASN.2015020132.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"840_CR6","doi-asserted-by":"publisher","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","volume":"310","author":"KR Kipp","year":"2016","unstructured":"Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol. 2016;310(8):F726\u201331. https:\/\/doi.org\/10.1152\/ajprenal.00551.2015.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"840_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","volume":"30","author":"JA Torres","year":"2019","unstructured":"Torres JA, Kruger S, Broderick C, Amarlkhagva T, Agrawal S, Dodam JR, et al. Ketosis ameliorates renal cyst growth in polycystic kidney disease. Cell Metab. 2019;30(6):1007\u201323. https:\/\/doi.org\/10.1016\/j.cmet.2019.09.012.","journal-title":"Cell Metab"},{"issue":"6","key":"840_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.16871020","volume":"16","author":"KL Nowak","year":"2021","unstructured":"Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol. 2021;16(6):908\u201315. https:\/\/doi.org\/10.2215\/CJN.16871020.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"840_CR9","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","volume":"25","author":"K Hopp","year":"2022","unstructured":"Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, et al. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022;25(1):103697. https:\/\/doi.org\/10.1016\/j.isci.2021.103697.","journal-title":"iScience"},{"issue":"15","key":"840_CR10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"840_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"19","key":"840_CR12","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.3390\/jcm12196341","volume":"12","author":"F Morioka","year":"2023","unstructured":"Morioka F, Nakatani S, Uedono H, Tsuda A, Mori K, Emoto M. Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease\u2014a retrospective single-arm case series study. J Clin Med. 2023;12(19):6341. https:\/\/doi.org\/10.3390\/jcm12196341.","journal-title":"J Clin Med"},{"issue":"1","key":"840_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160\u201372. https:\/\/doi.org\/10.1681\/ASN.2013101138.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"840_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125603","volume":"10","author":"S Kapoor","year":"2015","unstructured":"Kapoor S, Rodriguez D, Riwanto M, Edenhofer I, Segerer S, Mitchell K, et al. Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLoS ONE. 2015;10(4): e0125603. https:\/\/doi.org\/10.1371\/journal.pone.0125603.","journal-title":"PLoS ONE"},{"issue":"1","key":"840_CR15","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.1038\/s41467-022-35537-2","volume":"13","author":"SR Li","year":"2022","unstructured":"Li SR, Gulieva RE, Helms L, Cruz NM, Vincent T, Fu H, et al. Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease. Nat Commun. 2022;13(1):7918. https:\/\/doi.org\/10.1038\/s41467-022-35537-2.","journal-title":"Nat Commun"},{"issue":"5","key":"840_CR16","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol. 2017;28(5):1592\u2013602. https:\/\/doi.org\/10.1681\/ASN.2016040448.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"840_CR17","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.199","volume":"84","author":"X Wang","year":"2013","unstructured":"Wang X, Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, et al. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. Kidney Int. 2013;84(5):962\u20138. https:\/\/doi.org\/10.1038\/ki.2013.199.","journal-title":"Kidney Int"},{"issue":"4","key":"840_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","volume":"70","author":"JJ Neumiller","year":"2010","unstructured":"Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377\u201385. https:\/\/doi.org\/10.2165\/11318680-000000000-00000.","journal-title":"Drugs"},{"issue":"2","key":"840_CR19","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306(2):F188\u201393. https:\/\/doi.org\/10.1152\/ajprenal.00518.2013.","journal-title":"Am J Physiol Renal Physiol"},{"key":"840_CR20","doi-asserted-by":"publisher","first-page":"1118358","DOI":"10.3389\/fphar.2023.1118358","volume":"14","author":"F Sinha","year":"2023","unstructured":"Sinha F, Federlein A, Biesold A, Schwarzfischer M, Krieger K, Schweda F, et al. Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct. Front Pharmacol. 2023;14:1118358. https:\/\/doi.org\/10.3389\/fphar.2023.1118358.","journal-title":"Front Pharmacol"},{"issue":"1","key":"840_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19(1):102\u20138. https:\/\/doi.org\/10.1681\/ASN.2007060688.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"840_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s13730-021-00609-7","volume":"10","author":"S Watanabe","year":"2021","unstructured":"Watanabe S, Sawa N, Mizuno H, Yamanouchi M, Suwabe T, Hoshino J, et al. Development of osmotic vacuolization of proximal tubular epithelial cells following treatment with sodium-glucose transport protein 2 inhibitors in type II diabetes mellitus patients-3 case reports. CEN Case Rep. 2021;10(4):563\u20139. https:\/\/doi.org\/10.1007\/s13730-021-00609-7.","journal-title":"CEN Case Rep"},{"issue":"9","key":"840_CR23","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730\u20135. https:\/\/doi.org\/10.2337\/dc15-0355.","journal-title":"Diabetes Care"},{"issue":"5","key":"840_CR24","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2337\/dc13-2338","volume":"37","author":"BA Perkins","year":"2014","unstructured":"Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480\u20133. https:\/\/doi.org\/10.2337\/dc13-2338.","journal-title":"Diabetes Care"},{"issue":"9","key":"840_CR25","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.3390\/ijms22094374","volume":"22","author":"T Takata","year":"2021","unstructured":"Takata T, Isomoto H. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: renoprotective mechanisms beyond glycemic control. Int J Mol Sci. 2021;22(9):4374. https:\/\/doi.org\/10.3390\/ijms22094374.","journal-title":"Int J Mol Sci"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-023-00840-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:14:21Z","timestamp":1722507261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-023-00840-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s13730-023-00840-4","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"4 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have conflicts of interests to declare in regard to dapagliflozin. Regarding SGLT2 inhibitors other than dapagliflozin, KM has received honorariums for lecturing from Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K., and Nippon Boehringer Ingelheim. KM and ME have received research funding from Tanabe Pharma Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain results of any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for publication of her clinical data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}